← Eichor
Study identifier: NCT06999096 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia

Condition: Dystonia · Movement Disorders · Combined Dystonia  ·  Sponsor: University Hospital, Strasbourg, France

PhaseNA
Planned participants150
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS). Molecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-in some cases-targeted therapies. For instance, GNAO1-related dystonia may respond to deep brain stimulation, while dopa-responsive dystonia benefits from levodopa. Despite advances, srWGS has key limitations, especially for detecting repeat expansions, SVs, and phasing alleles. This likely explains the low diagnostic yield in dystonia compared to other neurological disorders, with over 70% of cases remaining unsolved. Long-read sequencing (lrWGS), such as Oxford Nanopore technology, overcomes many of these challenges by reading native DNA fragments thousands of bases long. It enables compre…

This description comes directly from the study's public registry record.

Talk to the study team

Thomas WIRTH, Doctor  ·  +33 3 88 12 89 19  ·  thomas.wirth@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (4)

CHU de Montpellier - Hôpital Gui de ChauliacMontpellier, FranceNot Yet Recruiting
CHRU NancyNancy, FranceRecruiting
Hôpital Pitié Salpêtrière- APHPParis, FranceNot Yet Recruiting
Hôpitaux Universitaires de StrasbourgStrasbourg, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06999096